Mannkind Corporation
MNKD Real Time Price USDRecent trades of MNKD by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by MNKD's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$30,000 Oct 20, 2023 Issue: Health Issues
-
$30,000 Jan 19, 2023 Issue: Health Issues
-
$30,000 Oct 18, 2022 Issue: Health Issues
-
$20,000 Apr 20, 2022 Issue: Health Issues
-
$30,000 Jan 20, 2022 Issue: Health Issues
-
$30,000 Oct 20, 2021 Issue: Medicare/Medicaid
-
$30,000 Jul 21, 2021 Issue: Medicare/Medicaid
-
$30,000 Jun 22, 2021 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
Estimated quarterly lobbying spending
MNKD Revenue by Segment or Geography
New patents grants
-
Patent Title: Multi-cartridge fluid delivery device Mar. 11, 2025
-
Patent Title: Dry powder inhaler and system for drug delivery Feb. 25, 2025
-
Patent Title: Methods for the synthesis of activated ethylfumarates and their use as intermediates Jan. 21, 2025
-
Patent Title: Fluid delivery device having an insertable prefilled cartridge Dec. 17, 2024
-
Patent Title: Blister package for pharmaceutical cartridges Oct. 29, 2024
-
Patent Title: Dry powder drug delivery system and methods Oct. 29, 2024
-
Patent Title: Formation of n-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic alpha-n-protected amino ester Jul. 30, 2024
-
Patent Title: Adapter for a fluid transfer device Jul. 23, 2024
-
Patent Title: Dry powder inhaler and system for drug delivery Jun. 04, 2024
-
Patent Title: Method of treating diabetes type 2 by administering ultrarapid acting insulin Jun. 04, 2024
-
Patent Title: Method of treating hypoglycemia events in diabetes treatment May. 14, 2024
-
Patent Title: Cartridge insertion mechanism for a fluid delivery device Apr. 09, 2024
-
Patent Title: Use of ultrarapid acting insulin Mar. 19, 2024
-
Patent Title: Diketopiperazine salts for drug delivery and related methods Jan. 16, 2024
-
Patent Title: Apparatus and method for cryogranulating a pharmaceutical composition Dec. 12, 2023
-
Patent Title: Interactive apparatus and method for real-time profiling of inhalation efforts Oct. 24, 2023
-
Patent Title: Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them Oct. 24, 2023
-
Patent Title: Time delay mechanism for a hydraulic drug delivery device Aug. 22, 2023
-
Patent Title: Communication accessory for a drug delivery device Aug. 08, 2023
-
Patent Title: Moving basal engine for a fluid delivery device Jun. 06, 2023
-
Patent Title: Fluid delivery device having an insertable prefilled cartridge May. 30, 2023
-
Patent Title: Hydraulically actuated pump for fluid administration May. 09, 2023
-
Patent Title: Dry powder drug delivery system and methods Apr. 11, 2023
-
Patent Title: Diketopiperazine microparticles with defined specific surface areas Mar. 21, 2023
-
Patent Title: Use of ultrarapid acting insulin Jan. 24, 2023
-
Patent Title: Methods for the synthesis of activated ethylfumarates and their use as intermediates Oct. 25, 2022
-
Patent Title: Apparatus, system and method for detecting and monitoring inhalations Oct. 25, 2022
-
Patent Title: Insufflation apparatus and methods Sep. 20, 2022
-
Patent Title: Formation of n-protected 3,6-bis-(4-aminoalkyl)-2,5,diketopiperazine Sep. 13, 2022
-
Patent Title: High capacity diketopiperazine microparticles and methods Sep. 06, 2022
-
Patent Title: Formation of n-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic α-n-protected amino ester May. 31, 2022
-
Patent Title: Inhalable dry powder pharmaceutical composition Apr. 19, 2022
-
Patent Title: Catalysis of diketopiperazine synthesis Apr. 05, 2022
-
Patent Title: Dry powder inhaler and system for drug delivery Feb. 08, 2022
-
Patent Title: Microcrystalline diketopiperazine compositions and methods Dec. 07, 2021
-
Patent Title: Dry powder inhaler and system for drug delivery Nov. 30, 2021
-
Patent Title: Composition and method for reducing hypoglycemia events in diabetes treatment Sep. 07, 2021
-
Patent Title: Reactor for producing pharmaceutical particles in a precipitation process Aug. 31, 2021
-
Patent Title: Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces Aug. 31, 2021
-
Patent Title: Apparatus and method for cryogranulating a pharmaceutical composition Aug. 03, 2021
-
Patent Title: Use of ultrarapid acting insulin May. 25, 2021
-
Patent Title: Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents May. 25, 2021
-
Patent Title: Heat-stable dry powder pharmaceutical compositions and methods May. 25, 2021
-
Patent Title: Diketopiperazine salts for drug delivery and related methods Feb. 09, 2021
-
Patent Title: Formation of n-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic α-n-protected amino ester Dec. 22, 2020
-
Patent Title: Methods for the synthesis of activated ethylfumarates and their use as intermediates Dec. 08, 2020
-
Patent Title: Method of treating diabetes type 2 by administering ultrarapid acting insulin Dec. 08, 2020
-
Patent Title: Use of ultrarapid acting insulin Sep. 15, 2020
-
Patent Title: Diketopiperazine microparticles with defined specific surface areas Sep. 15, 2020
-
Patent Title: Dry powder inhaler and system for drug delivery Aug. 25, 2020
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to MNKD
Recent picks made for MNKD stock on CNBC
ETFs with the largest estimated holdings in MNKD
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $MNKD stock a Buy, Sell, or Hold?
- What is the price target for $MNKD stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $MNKD stock?
- Who owns the most shares of $MNKD stock?
- What funds own $MNKD stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view MNKD Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.